关键词：视网膜静脉阻塞；视网膜静脉；血流；糖尿病；高脂血症
摘 要：Retinal vein occlusion is the blockage of retinal veins leading to the blockage of blood flow in the retina. This disease is likely to affect individuals suffering from hypertension, diabetes mellitus,or hyperlipidemia. Retinal vein occlusion is one of the most common vascular disorders, as well as one of the most common causes of blindness in diabetic retinopathy patients. There are two types of retinal vein occlusion: central retinal vein occlusion and branch retinal vein occlusion. Central retinal vein occlusion can further be divided into ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

Product Portfolio

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Pipeline Portfolio

08. Rate of Incidence and Prevalence

09. Market Segmentation by Type of Therapy

09.1.1 Biologics

09.1.2 Corticosteroids

10. Market Segmentation by Route of

Administration

10.1.1 Intravitreal

10.1.2 Intravenous

11. Market Segmentation by Dosage Form

11.1.1 Solutions

11.1.2 Implant

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

20.1 Competitive Scenario

20.1.1 Key News

20.1.2 Mergers and Acquisitions

20.2 Market Share Analysis 2013

20.2.1 Other Prominent Vendors

21. Key Vendor Analysis

21.1 Bayer

21.1.1 Key Facts

21.1.2 Business Overview

21.1.3 Business Segmentation

21.1.4 Business Segmentation by Revenue 2012 and 2013

21.1.5 Sales by Geography

21.1.6 Business Strategy

21.1.7 Key Information

21.1.8 SWOT Analysis

21.1.9 Strengths

21.1.10 Weaknesses

21.1.11 Opportunities

21.1.12 Threats

21.2 F. Hoffmann-La Roche

21.2.1 Key Facts

21.2.2 Business Overview

21.2.3 Business Segmentation

21.2.4 Business Segmentation by Revenue 2012 and 2013

21.2.5 Sales by Geography

21.2.6 Business Strategy

21.2.7 Key Information

21.2.8 SWOT Analysis

21.2.9 Strengths

21.2.10 Weaknesses

21.2.11 Opportunities

21.2.12 Threats

21.3 Novartis

21.3.1 Key Facts

21.3.2 Business Overview

21.3.3 Business Segmentation by Revenue 2013

21.3.4 Business Segmentation by Revenue 2012 and 2013

21.3.5 Sales by Geography

21.3.6 Business Strategy

21.3.7 Key Developments

21.3.8 SWOT Analysis

21.3.9 Strengths

21.3.10 Weaknesses

21.3.11 Opportunities

21.3.12 Threats

21.4 Regeneron Pharmaceuticals

21.4.1 Key Facts

21.4.2 Business Overview

21.4.3 Product Segmentation

21.4.4 Product Segmentation by Revenue

21.4.5 Business Strategy

21.4.6 Key Information

21.4.7 SWOT Analysis

21.4.8 Strengths

21.4.9 Weaknesses

21.4.10 Opportunities

21.4.11 Threats

22. Other Reports in this Series